Firm gains facility in the U.K. that focuses on evaluation of biopharmaceuticals and vaccines.

Millipore has acquired BioAnaLab to expand its biopharmaceutical services into Europe. Its facility in Oxford, U.K., specializes in the analysis of biologics and vaccines. It will complement Millipore’s existing site for large molecule bioanalytical services in St. Charles, MO.

“As an increasing number of biologics enter the pipeline, companies are leveraging Millipore’s ligand-binding assay expertise to help them evaluate the efficacy of these drugs and achieve regulatory compliance,” says Jonathan DiVincenzo, President of Millipore’s Bioscience Division.

“Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market. BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines.”

BioAnaLab was spun out of the University of Oxford in 2002. Services offered include assay transfer/development, validation and sample analysis, pharmacokinetics/toxicokinetics, immunogenicity, biological potency, and vaccine services. Millipore will bring substantial expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area.

Previous articleBridges that Indian Biosimilar Makers Must Cross to Prosper in International Markets
Next articleNewcastle University to Mine Horizon’s X-MAN Cell Lines for Cancer Imaging Biomarkers